Neurocrine Biosciences Cash Flow Statement
NBIX / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
Neurocrine Biosciences generated $783M in operating cash flow and $749M in free cash flow in FY2025. Free cash flow margin was 26.2% of revenue.
Based on SEC 10-K filings.
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $478.6M | $341.3M | $249.7M | $154.5M | $89.6M | $407.3M | $37.0M | $21.1M | -$142.5M | -$141.1M | -$88.9M | -$60.5M | -$46.1M | $5.0M | $37.6M |
| Depreciation & Amortization | - | - | - | - | - | - | - | $4.0M | $2.4M | $1.5M | $1.0M | $827.0K | $671.0K | $657.0K | $694.0K |
| Operating Cash Flow | $782.7M | $595.4M | $389.9M | $339.4M | $256.5M | $228.5M | $147.0M | $101.4M | -$94.3M | -$106.2M | -$38.0M | -$47.1M | -$29.6M | -$35.3M | -$698.0K |
| Capital Expenditures | $34.0M | $38.2M | $28.3M | $16.5M | $23.4M | $10.9M | $14.7M | $24.8M | $6.9M | $4.1M | $1.9M | $1.6M | $545.0K | $971.0K | $750.0K |
| Free Cash Flow | $748.7M | $557.2M | $361.6M | $322.9M | $233.1M | $217.6M | $132.3M | $76.6M | -$101.3M | -$110.3M | -$39.9M | -$48.8M | -$30.2M | -$36.3M | -$1.4M |
| Share Buybacks | $167.7M | $300.0M | $0 | $0 | - | - | - | - | - | - | - | - | - | - | - |
| FCF Margin | 26.2% | 23.7% | 19.2% | 21.7% | 20.6% | 20.8% | 16.8% | 17.0% | - | -735.3% | -202.0% | - | -1033.0% | -68.2% | -1.9% |